Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...
STOCKHOLM, SE / ACCESS Newswire / March 5, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...
Innovation Investment Capital Limited Partnership (IIC), the Cardiff Capital Region (CCR) backed fund, and the Development ...
Conference Call Begins at 4:30 p.m. Eastern Time TodayEMERYVILLE, Calif.--(BUSINESS WIRE)--$OABI #OABI--OmniAb, Inc. (NASDAQ: ...
Peer reviewed - observational study - humansThe Covid pandemic disrupted children’s ability to self-regulate - according to ...
Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D ...
France has launched a fast track clinical trial approval pathway that could reduce authorisation times to as little as 14 ...
OverviewThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value of USD ...
Antiverse has raised $9.3M in Series A funding to expand its AI driven antibody discovery platform and has entered a research ...
Overview of Medical Radiation Shielding MarketThe Medical Radiation Shielding Market plays a critical role in ensuring safety ...
Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 –– FREEDOM2 trial open in South Korea, Australia, and New Zealand –– Well-funded with ...
LAFAYETTE, LA / ACCESS Newswire / March 4, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results